PROCEPT BioRobotics (NASDAQ:PRCT) Shares Climb 6.6% – Time to Buy?

Posted by Francis Steltz on Oct 1st, 2026

PROCEPT BioRobotics Corporation (NASDAQ:PRCT – Get Free Report)’s share price was up 6.6% during mid-day trading on Tuesday. The company traded as high as $18.07 and last traded at $18.39. Approximately 1,028,044 shares changed hands during mid-day trading, a decline of 33% from the average session volume of 1,533,729 shares. The stock had previously closed at $17.25.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Leerink Partners cut PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $31.00 to $29.00 in a research note on Thursday, June 11th. William Blair downgraded PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Finally, UBS Group lowered PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price target for the company. in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $25.09.

View Our Latest Analysis on PRCT

PROCEPT BioRobotics Price Performance

The business’s 50 day moving average price is $19.96 and its two-hundred day moving average price is $22.79. The stock has a market cap of $1.02 billion, a P/E ratio of -9.29 and a beta of 0.91. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The company had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.PROCEPT BioRobotics’s quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.35) earnings per share. As a group, sell-side analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Larry Wood acquired 23,900 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares in the company, valued at $498,315. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 1,043 shares of company stock worth $21,851 in the last 90 days. Insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in PROCEPT BioRobotics in the second quarter worth $109,961,000. Wellington Management Group LLP grew its position in PROCEPT BioRobotics by 47.9% during the 2nd quarter. Wellington Management Group LLP now owns 1,274,004 shares of the company’s stock valued at $28,767,000 after purchasing an additional 412,399 shares during the last quarter. Jupiter Topco LLC bought a new stake in PROCEPT BioRobotics during the 2nd quarter valued at about $24,914,000. Rhenman & Partners Asset Management AB increased its stake in PROCEPT BioRobotics by 56.7% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 611,000 shares of the company’s stock valued at $19,222,000 after purchasing an additional 221,000 shares in the last quarter. Finally, William Blair Investment Management LLC purchased a new position in PROCEPT BioRobotics in the second quarter worth about $16,020,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for urologic care. The company’s primary focus is the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms.

Its flagship product is the AQUABEAM Robotic System, which uses image guidance, robotics, and high-velocity waterjet technology to remove targeted prostate tissue without the use of a traditional cutting instrument.